A whole-genome survey of 959 primary prostate cancers has yielded eight integrated mutational footprints — IMFs — that together account for the mutational processes driving 85% of primary prostate cancer genomes, according to a Nature study profiled by Inside Precision Medicine. The work, co-led by Joachim Weischenfeldt, PhD, of the University of Copenhagen's Biotech Research & Innovation Centre and Rigshospitalet, reframes prostate cancer heterogeneity as the output of a tractable set of biological processes rather than a catalogue of isolated lesions. The analytical leverage comes from treating single-base substitutions, insertion–deletions, copy number variants, and complex structural variants as one integrated dataset rather than as separate inventories.
What the eight IMFs capture
The integrated mutational footprints map predominantly onto three biological axes: androgen-driven hormone signaling, failures in DNA replication and repair, and age-related mutagenesis. That stratification matters because it lets clinicians move beyond single-gene biomarkers toward a process-level reading of any given tumor.
When the authors interrogated the clinical data layered onto the genomic footprints, four IMFs present in 37% of primary tumors tracked significantly with shorter time to metastasis. Among these were signatures of reactive oxygen-species-driven mutagenesis and homologous recombination deficiency — two process classes that already carry therapeutic implications in the molecular oncology toolkit. Two further IMFs partitioned cleanly by age: one predominated in early-onset disease, a separate one in late-onset tumors. The late-onset IMF additionally predicted sensitivity to androgen receptor pathway inhibitors, suggesting a route to biomarker-guided selection in a population where overtreatment has been a longstanding clinical concern.
Operational read for the laboratory
For molecular diagnostics and pathology teams, the most consequential detail in the Inside Precision Medicine report is operational rather than purely biological. Weischenfeldt is explicit that the framework runs on whole-genome sequencing data that several health systems already generate for cancer patients — it does not require a new assay. "What we are proposing is to read existing data differently, not to build a new test from scratch," he told the publication.
That distinction reframes the IMF paradigm as a bioinformatics and clinical interpretation problem rather than a capital expenditure problem for laboratories. Validation pipelines, curated reference signature sets, and reporting standards will need to mature before IMFs can enter prospective risk-stratification workflows; the authors themselves caution that "more extensive and well-powered prospective biomarker-driven studies are warranted" before clinical adoption. "Our goal is to tailor treatment to each individual patient's disease, and this brings us one step closer to making that a reality," Weischenfeldt added.
Signal across the precision-oncology landscape
The IMF publication lands against a backdrop of uneven translational traction in molecular oncology. Bioengineer.org has reported that ESR1 testing remains rare in metastatic breast cancer even as resistance mutations continue to emerge, underscoring the persistent gap between genomic insight and routine clinical practice. Separately, finance.biggo.com has tracked the FDA's override of an advisory panel to approve AstraZeneca's liquid-biopsy-guided breast cancer therapy Etcamah — a signal that regulators are increasingly willing to act on molecularly stratified evidence ahead of fully mature biomarker frameworks.
The trajectory is consistent: the precision-oncology pipeline is generating more clinically actionable signal than current laboratory workflows reliably convert into treatment decisions. The IMF architecture offers a template for closing that gap, provided reference laboratories invest in the interpretive infrastructure — curated signature databases, validated variant callers for complex structural events, and reporting structures that translate process-level findings into clinician-actionable risk categories. As the broader regulatory environment tilts toward molecularly guided approvals, the laboratories that operationalize frameworks like IMFs first will set the analytical benchmark for the next cycle of biomarker-driven stratification.